Thursday, 9 May 2019

The Magic Bullet

The Magic Bullet by Harry Stein emerges as a compelling work of speculative fiction—one that deftly interlaces medical science, corporate ambition, and ethical introspection into a narrative both taut and quietly disquieting. At once a page-turning thriller and a sobering cautionary tale, the novel probes humanity’s perennial fascination with miracle cures—and the treacherous moral terrain that so often shadows them.

Set in a world uncannily proximate to our own, poised on the cusp of a biomedical revolution, the story orbits around the discovery of a revolutionary drug—an innovation that promises to vanquish a devastating disease with almost surgical precision. The titular “magic bullet,” a phrase inherited from early 20th-century scientific idealism, gestures toward a treatment capable of annihilating disease without collateral damage to the host. Stein appropriates this seductive notion and magnifies it into a high-stakes meditation on science, power, and the fragility of human ethics.

At the heart of the narrative stands Dr. Daniel Logan, a brilliant yet internally conflicted biomedical researcher ensconced within a cutting-edge pharmaceutical enterprise racing against time—and rivals—to deliver a cure for a lethal illness afflicting millions. The drug in question is no mere therapeutic intervention; it is conceived as a definitive cure, engineered with breathtaking specificity. Logan begins as an archetypal idealist, animated by the noble impulse to alleviate human suffering. Yet his work unfolds under the watchful, and increasingly disquieting, gaze of a corporate behemoth whose motivations are anything but purely altruistic. Early clinical trials yield astonishing results: patients once consigned to despair exhibit rapid, almost miraculous recoveries.

But as the trials widen in scope, fissures begin to appear beneath the surface of this scientific triumph. A small but troubling cohort of patients develops severe and inexplicable side effects—neurological disturbances, unsettling personality alterations, and, in certain cases, fatal outcomes. These anomalies are quietly buried by the corporation, wary that even the faintest hesitation might cede advantage to competitors. Logan, increasingly plagued by doubt, embarks upon a deeper investigation into the drug’s inner workings. What he uncovers is profoundly unsettling: the “magic bullet” operates with a level of biological intrusion far exceeding initial assumptions, interacting with genetic and neurological pathways in ways that defy full comprehension. It does not merely cure—it transforms.

Running parallel to Logan’s moral and intellectual descent is the story of a patient whose seemingly miraculous recovery is heralded as the public triumph of the drug. Through her, Stein deftly humanizes the abstract, illuminating both the luminous promise and the concealed cost of such breakthroughs. As pressure mounts—from corporate executives, regulatory authorities, and an insatiable media—Logan finds himself ensnared in an agonizing ethical dilemma: to expose the truth and risk derailing a potentially life-saving innovation, or to remain complicit in silence, allowing progress to proceed despite its latent dangers.

In dismantling the seductive myth of the flawless scientific solution, Stein transforms the “magic bullet” into a potent metaphor for human hubris—the enduring belief that nature can be outmaneuvered without consequence. The novel’s central tension resides in the uneasy interplay between scientific integrity and corporate imperatives. Notably, the pharmaceutical conglomerate is not rendered as a caricature of villainy, but rather as a system driven by structural compulsions—shareholder expectations, competitive pressures, and the relentless pursuit of innovation.

Logan’s journey is, at its core, a moral odyssey. His evolution from earnest idealism to chastened disillusionment reflects the profound burden borne by those who operate at the frontiers of knowledge. Stein resists simplistic binaries, portraying science as neither inherently benevolent nor malevolent, but as an ambivalent force—capable of salvation or destruction, contingent upon its stewardship.

Stylistically, Stein’s prose is marked by a lucid precision that privileges clarity over ornamentation. His ability to render complex scientific ideas intelligible without diluting their nuance is particularly commendable. The narrative pacing is measured yet inexorable, accumulating tension as ethical quandaries deepen and the stakes escalate.

The Magic Bullet ultimately stands as a thoughtful and unsettling exploration of the promises—and perils—of modern science. In crafting a narrative that is as intellectually provocative as it is narratively engrossing, Stein compels the reader to confront disquieting questions about progress, responsibility, and the often invisible cost of innovation.

Class Action Suits

Section 245 of the companies act, 2013 is a new addition in the 2013 Act, which provides for a class action suit to be filed by such number of member(s)/ depositor(s) against the company. Vast powers have been given in the section against the company. The application under this section has to be made to the National company law tribunal (NCLT). But the Rules under this section which is in the National Company Law Tribunal Rules did not hitherto specify how many members/ depositors are required in order to file an application.

By an amendment to the NCLT Rules, the MCA has sorted that matter out.

So the class action suit can be brought by at least 5% of the total number of members in a company or 100 members, whichever is less.

Alternatively it can be bought by member or members holding not less than 5% of the issued share capital of the company in case of unlisted company and 2% in case of listed company.


In case of depositors, it is

5% of the total number of depositors or 100 depositors whichever is less OR

depositor or depositors to whom the company owes 5% of the total deposits of the company.

The copy of the notification can be found at the MCA site.




Strike off Rules

MCA has vide its notification dated 8th May, 2019 made some amendments to the rules governing strike off of companies. This is the Companies (Removal of Names of Companies from Register), Rules, 2016.

Well, first and foremost, they have doubled the fees for making an application for strike off from Rs.5000/- to Rs.10,000/-.

Secondly, they have clarified that all pending annual e-forms have to be filed by the company before making an application for strike off in form STK-2. Hitherto, this was not required and different ROCs interpreted it differently. This brings in uniformity. But MCA should have provided for closure of the companies without having to file the baggage annual e-forms. It will lead to huge cost to the company to file all delayed annual e-forms because the late fees is now Rs.100 per day from 1st July, 2018 onwards. It is not ease of doing business.

Thirdly if the company intends to file an STK-2 application after the MCA has initiated steps to close down the company, then also the company has to file all pending and overdue annual e-forms to make it upto date.

However, once the MCA has issued a notice to the company in form STK-7 after initiating closure action against the company as per above, then the company cannot file the form STK-2. Meaning once the action gets initiated at the MCA end, then the company cannot subvert it by filing a STK-2 application.

The accounts of the company which has to be attached to the form STK-2 is provided in form STK-8.

The copy of the notification is available at the MCA site. 

A Man Alone

This post is written in Aari, a  South Omotic language, spoken in the North Omo zone of the Southern Nations, Nationalities, and Peoples...